MCOV B Share Price | Medicover AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

45.98 k

Shareholding (Jun 2024)

FII

0.18%

Held by 1 FIIs

DII

99.82%

Held by 0 DIIs

Promoter

0.00%

Compare Medicover AB with Similar Stocks

AddLife AB Ambea AB Humana AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Debt Company with a Debt to Equity ratio (avg) at times

High Debt Company with a Debt to Equity ratio (avg) at times

Healthy long term growth as Net Sales has grown by an annual rate of 20.29%

With a growth in Net Profit of 108.14%, the company declared Very Positive results in Dec 25

With ROE of 12.45%, it has a fair valuation with a 7.38 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 31,177 Million (Small Cap)

P/E

59.00

Industry P/E

Dividend Yield

0.03%

Debt Equity

1.66

Return on Equity

14.17%

Price to Book

5.40

Revenue and Profits:

Net Sales:

6,697 Million

(Quarterly Results - Dec 2025)

Net Profit:

189 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-14.52%

6 Months

-27.58%

1 Year

-5.84%

2 Years

38.77%

3 Years

12.91%

4 Years

-4.68%

5 Years

-1.37%

Medicover AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

20.29%

EBIT Growth (5y)

21.80%

EBIT to Interest (avg)

3.30

Debt to EBITDA (avg)

1.57

Net Debt to Equity (avg)

1.35

Sales to Capital Employed (avg)

1.65

Tax Ratio

28.27%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.18%

ROCE (avg)

11.54%

ROE (avg)

9.18%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.38

EV to EBIT

33.60

EV to EBITDA

12.22

EV to Capital Employed

3.25

EV to Sales

1.89

PEG Ratio

0.39

Dividend Yield

0.03%

ROCE (Latest)

9.68%

ROE (Latest)

12.45%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.18%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 4.79% vs 20.60% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 122.56% vs -13.78% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,697.40",
          "val2": "6,391.30",
          "chgp": "4.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "986.50",
          "val2": "861.30",
          "chgp": "14.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "175.20",
          "val2": "173.60",
          "chgp": "0.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-19.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "189.40",
          "val2": "85.10",
          "chgp": "122.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "57.50%",
          "val2": "45.00%",
          "chgp": "1.25%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 10.03% vs 19.35% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 381.86% vs -20.93% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26,322.10",
          "val2": "23,922.70",
          "chgp": "10.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,106.40",
          "val2": "3,291.40",
          "chgp": "24.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "708.40",
          "val2": "672.50",
          "chgp": "5.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-220.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "804.70",
          "val2": "167.00",
          "chgp": "381.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "65.50%",
          "val2": "42.80%",
          "chgp": "2.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

6,697.40

6,391.30

4.79%

Operating Profit (PBDIT) excl Other Income

986.50

861.30

14.54%

Interest

175.20

173.60

0.92%

Exceptional Items

0.00

-19.50

100.00%

Consolidate Net Profit

189.40

85.10

122.56%

Operating Profit Margin (Excl OI)

57.50%

45.00%

1.25%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 4.79% vs 20.60% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 122.56% vs -13.78% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

26,322.10

23,922.70

10.03%

Operating Profit (PBDIT) excl Other Income

4,106.40

3,291.40

24.76%

Interest

708.40

672.50

5.34%

Exceptional Items

0.00

-220.70

100.00%

Consolidate Net Profit

804.70

167.00

381.86%

Operating Profit Margin (Excl OI)

65.50%

42.80%

2.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 10.03% vs 19.35% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 381.86% vs -20.93% in Dec 2024

All Annual Results

Company CV

About Medicover AB

Medicover AB

Pharmaceuticals & Biotechnology

Medicover AB is a Sweden-based healthcare and diagnostic services provider. It offers a broad range of healthcare services and hub-and-spoke diagnostic laboratory network, supported by proprietary software and information systems infrastructure. The Company offers its services through two divisions: Healthcare Services and Diagnostic Services. The Healthcare Services division offers services ranging from primary care to specialist outpatient and inpatient care. The care is delivered mainly through Medicover’s own network of clinics and medical facilities. The Diagnostic Services division offers a broad range of diagnostic laboratory testing for humans and some veterinary services across all main clinical pathology specialties. The Company focuses primarily on such markets, as Poland, Germany, Romania, Ukraine.

Company Coordinates

Company Details

Riddargatan 12 3Tr , STOCKHOLM None : 114 35

Tel: 46 8 4001760046 8 40017606

https://www.medicover.com

Registrar Details